The fact that advanced NSCLC has a relatively even distribution of PD-L1 expression in conjunction with the fact that there are similar clinical indications for checkpoint inhibitors could render it difficult for physicians to make clinical decisions. The gene discussed is CD274; the disease is non-small cell lung carcinoma.